Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Top Cited Papers
- 10 September 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (26), 6285-6295
- https://doi.org/10.1200/jco.2005.05.010
Abstract
Myeloid malignancies are clonal disorders that are characterized by acquired somatic mutation in hematopoietic progenitors. Recent advances in our understanding of the genetic basis of myeloid malignancies have provided important insights into the pathogenesis of acute myeloid leukemia (AML) and myeloproliferative diseases (MPD) and have led to the development of novel therapeutic approaches. In this review, we describe our current state of understanding of the genetic basis of AML and MPD, with a specific focus on pathogenetic and therapeutic significance. Specific examples discussed include RAS mutations, KIT mutations, FLT3 mutations, and core binding factor rearrangements in AML, and JAK2 mutations in polycythemia vera, essential thrombocytosis, and chronic idiopathic myelofibrosis.Keywords
This publication has 178 references indexed in Scilit:
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)Leukemia, 2004
- The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane DomainMolecular Cell, 2004
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- Disruption of differentiation in human cancer: AML shows the wayNature Reviews Cancer, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002
- t(5;12)(q31;p12) A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemiaCancer Genetics and Cytogenetics, 1993